ObvioHealth primary logo.
Schedule an Intro

A DCT Team & Tech You Can Trust

Virtual Site Expertise. Deep Experience. Clinically Focused Tech.

Choosing a DCT approach for your study can be daunting. We’ve cut through all the noise to make trial decentralization more achievable. ObvioHealth clients appreciate our combination of experienced clinical researchers, supportive patient assistance teams, and pioneering technology. This is our winning prescription for seamless clinical trials.

Schedule an Intro

Our Tech & Team drive higher retention, compliance, and adherence rates for trials that are more likely to be completed on time and on budget.

88%

Percent Retention Rate

Percent of participants enrolled in an ObvioHealth trial that complete the study

90%

ePRO

Percentage average of ePRO compliance in completed ObvioHealth studies

Virtual Site Expertise.

ObvioHealth’s COACH (Clinical Oversight And Coordination Hub) team operates in the same way as the clinicians you’d find at a site for a traditional trial. The difference is that our team communicates with, and cares for, patients virtually—using the cutting-edge digital technology that has been put at their disposal.

Built-for-Purpose Tech.

Our platform has been developed by clinical scientists and healthcare technologists to capture better outcomes by reducing friction. It incorporates real-time safety monitoring and delivers more reliable endpoints.

Experienced Clinical Team.

As one of the first companies to launch decentralized trials, ObvioHealth has been recognized by Everest, Scrip, and DTR as a leader in the field, providing guidance based on experience, across more than 40 decentralized studies, on how to design and execute for success.

Humanizing DCTs with an Experienced Virtual Site Team

ObvioHealth’s COACH (Clinical Oversight And Coordination Hub) team sits at the heart of our success. Our CRO roots have taught us that tech alone is not sufficient to deliver successful studies. So, we designed our tools to be run by our own experienced in-house team. The platform enables the team to provide support and assistance, reducing the need for visits to clinics and enabling the real-time monitoring of adverse events. Integrated devices capture data on vital signs which can be visualized in real time on data dashboards. Patients regularly contact the COACH team to ask questions, and the support team also reaches back out to them when they see a drop-off in reporting to address any concerns and encourage them to comply with the study protocol.

Meet our COACH Team

With the COACH team, patients have multiple ways to stay connected and informed during their studies through virtual chats, email, or phone calls—a COACH member is always an arm’s length away.

Deep Clinical Operations Experience

At ObvioHealth, we believe experience is key. We have developed and validated over 250 ePRO/PRO solutions across various therapeutic areas, leading to successful outcomes and endpoints.

17 Therapeutic Areas

Over the past 5 years, we have worked across 17 therapeutic areas, enabling us to gain powerful insights into how to adapt decentralized trials to specific protocols.

Cardiology therapeutic icon. Dermatology therapeutic icon.GI therapeutic icon. Men's Health therapeutic icon. Mental health therapeutic icon.Nutrition therapeutic icon.Oncology therapeutic icon.Pediatrics therapeutic icon.Sleep therapeutic icon.Virology therapeutic icon. Women's Health therapeutic icon.

Client Roster

In this short time, 7 of our 21 clients have given us repeat business—the greatest proof of satisfaction

Anatara logo.A. Vogel Logo.Bayer logo.Danoone Logo. DSM logo.entrinsic health logo.Friesland campina logo.General mills logo.
Janssen logo.Lycored logo.Megafoods logomithra logo. Mizkan logo.pfizer logo.RedHill Biopharma Logo.Renovia Logo.

40+ Studies in 28 Countries

ObvioHealth is a truly global organization. We have run trials in 28 countries across 5 continents.

Case Study #1

Studying the Efficacy of a Medical Device on Urinary Incontinence

Pelvic floor muscle training (PFMT), or "Kegel" exercises, is considered the most effective, non-invasive treatment for stress urinary incontinence and stress predominant mixed urinary incontinence. However, more than 75 percent of women perform PFMT exercises incorrectly, even with verbal or written instructions.

Objective:

Evaluate the efficacy of a Class II digital therapeutic device compared to standard care of PFMT exercises to treat SUI/SMUI.

Methodology:

The first fully virtual study to be run in the urogynocology space, this prospective, randomized controlled study recruited participants via digital media targeting and signed them via electronic informed consent (eIC), using the ObvioHealth app to complete enrollment. Instruction material (video plus explanatory placard) was provided for the Kegel group; those in the treatment arm performed PFMT with the device's assistance.

Patients answered validated questionnaires via the app to assess changes in health outcomes. Exercise adherence, patient perceptions, and AEs/SAEs were monitored regularly via the app and visualized on live platform dashboards by our COACH (Clinical Operations And Coordination Hub) team.   

There were no required office visits in this study. Upon randomization, subjects received three scheduled phone calls from the COACH team for education on PFMT exercises. For the remainder of the study, patients received additional phone calls regarding the treatment plan and safety monitoring.

Results:

Recruitment was completed with 350 participants enrolling in the trial in just 3.5 months. Regular interactions with our COACH team engaged and encouraged patients throughout the study, resulting in an 89% retention rate and a 95% ePRO compliance rate. The study delivered statistically significant results for the device versus control Kegel groups for both primary outcomes. We would not have had this outcome without it being a virtual study. In contrast, I was running an FI study and drop-off was dramatic. We probably completed 60%.
- Robin Sutherland, VP of Clinical Operations

Case Study #2

Next-Generation Data Collection to Determine the Efficacy of a COVID-19 Treatment

Objective:

RedHill Biopharma seeks to evaluate the safety and efficacy of an oral investigational drug on non-hospitalized COVID-19 patients.

Methodology:

Our team of clinical researchers and software engineers designed a study to allow patients to participate from home while maintaining a high level of monitoring. Patients are enrolled through a clinical site and sent home with the study drug plus several devices to collect both telemetric and patient-reported information to measure safety and efficacy signals.

Vitals measured via devices:
Temperature
Respiratory rate
Heart/pulse rates

Patients are given the option of coming back to the site or of having healthcare nurses conduct in-home visits to collect blood samples for certain laboratory parameters, perform virus PCR swabs, and verify that patients are using devices correctly.

Results:

Part A of the study is currently under way to optimize dosing. Part B is slated to begin in early 2022.

Case Study #3

Assessing the Efficacy of a New Treatment for Pre-Hypertension

Objective:

A multinational company needed to assess the safety and efficacy of a treatment for pre-hypertensive adults and those at high risk of cardiovascular disease.

Methodology:

Our clinical operations team designed a hybrid study to include remote data collection to reduce the number of site visits required in a traditional study. We were able to quickly and cost effectively reach the desired cohort through digital media recruitment by digitally targeting patients more likely to have high blood pressure (eg: had purchased a blood pressure cuff and/or had visited sites providing information on hypertension).

Emphasis was also placed on ensuring the representation of African American patients, as this population over-indexes for high blood pressure. Between site visits, subjects completed daily questionnaires, and our COACH (Clinical Oversight And Coordination Hub) team tracked any changes in health status.

Results:

• Successful recruitment of a diverse population: 41% Caucasian, 39% African American, 20% other races.
• Minimization of site visits via remote monitoring facilitated the collection of 56,286 data points reviewed in real time.
• The virtual team’s regular engagement with patients helped to achieve an 89% retention rate.

Left Carousel Arrow icon.
Right carousel arrow icon.

Meet our Team

Our leadership team has an aggregated 135 years’ experience in designing and running clinical trials, designing and operating successful health tech platforms, and optimizing tools and diagnostics to better measure outcomes.

Ivan Jarry Headshot

Ivan Jarry

CEO

Ivan has a proven track record of creating and growing 40+ companies in the health innovation space (Consulting, CRO, Digital Health, and Biotech). Over the course of his career, Ivan has consistently disrupted health categories by identifying market gaps and leading organizations to scalable success.

Craig Gravina Headshot

Craig Gravina

CTO

Craig has over 25 years of experience developing highly innovative platforms, products, and disruptive technologies within healthcare and life sciences, including a digital therapy platform for Ieso Digital and cognitive assessment solutions at Cogstate. Craig also led the development of an analytics and population health platform and portfolio at AllScripts.

Matty Culbreth-Notaro Headshot

Matty Culbreth-Notaro

SVP Global Operations

Matty was one of the earliest employees of ObvioHealth and brought nearly 30 years of experience in clinical research to the team. In her previous roles, Matty developed and implemented clinical research programs for multi-therapeutic area practices and hospitals across the country. She has managed advanced research programs specializing in phases I-IV, device, post-approval, observational, and decentralized clinical trials.

Scott Clark Headshot

Scott Clark

Chief Commercial Officer

Scott brings 25 years of expertise in the pharmaceutical and CRO industries to ObvioHealth, including stints at Pfizer and Quintiles where he developed new business entities. He possesses extensive drug development expertise from preclinical through commercialization, including M&A and product/service launches on a global scale, and is a therapeutic expert in regenerative medicine, oncology, ID, and CNS, among others.

Susan Dalabrida Headshot

Susan Dallabrida, Ph.D.

VP of Clinical Science and Innovation

With 25+ years of experience as a leader in clinical trials, healthcare, and eClinical technology, Susan is an expert in clinical innovation. She brings to ObvioHealth her expertise in patient centricity and engagement for data capture, with a focus on improving data quality and completeness.

Parth Shah Headshot

Dr. Parth Shah

Medical Director

Parth has over 12 years of diverse clinical and research experience in both academic and industry settings. He has served as the lead Principal Investigator (PI) and Medical Monitor (MM) across 12+ therapeutic areas and 20+ hybrid and decentralized clinical trials (DCTs).

Hawley Linke Headshot

Hawley Linke, Ph.D.

Sr. VP of Scientific Affairs

With 35+ years of experience driving science in clinical, pharmaceutical, and academic environments, Hawley is an expert in scientific affairs. She has worked at top-tier healthcare companies and institutions specializing in clinical research, laboratory-based genetic engineering, gene expression studies, virology, nutrition, technology assessment, and science and medical communication.

Marcos Dopazo Headshot

Marcos Dopazo

Sr. Medical Director

Marco specializes in cardiovascular diseases and emergency room medicine. Dr. Dopazo leverages his 13 years of experience to provide medical expertise and oversight for clinical trials, ensuring the clinical integrity of trial subjects and providing safety accountability across the duration of studies.

Pioneering Technology Designed for the Real World

We know that capturing quality outcomes and effectively monitoring the safety of a clinical trial requires more than traditional ePRO solutions can offer. Our clinically focused technology platform reduces friction in outcomes capture, reduces patient burden, and leads to more reliable endpoints.

Our purpose-built app and platform incorporates a modular design that enables us to more easily adapt to each project’s parameters. We have structured the platform to provide a range of options for each step in the trial journey. Our experienced team can help you to choose and assemble the components in the best way to fit the needs of your trial. Because these options are preconfigured, the need for customized programming can be reduced, or even eliminated, with positive impacts on both timing and budget.

Our app walks patients through the clinical trial process step by step. From enrollment and eConsent to patient training and study questionnaires, our user experience makes participation easy. User-friendly questionnaires and diaries with smoother navigation make it easy for patients to enter their data at the moment an event occurs. At the push of a button, they can capture the duration, frequency, and intensity of a symptom.

ObvioHealth’s virtual environment integrates with apps and devices that enable patients to measure heart rates, blood pressure, respiration rates, weight, temperature, oxygen, and glucose levels, and even take ECGs from home. Test kits, devices, and instructions are shipped to the patient, and virtual training sessions ensure they are being used correctly. This opens a world of opportunity for the more convenient capture of accurate real-time data.

An study dashboard scrolling through graphs displaying a patient's vitals.

Once all the data has been captured, ObvioHealth’s end-to-end capabilities store everything in a single system. Data is displayed in real time on easy-to-read dashboards that can be viewed by the study staff and the sponsor. These dashboards also immediately alert the study staff to possible adverse events and lapses in compliance. Because our data is all in one place and minimal data cleaning is needed at the end of a study, our average time between LPO and database lock is 7 to 10 business days.

Meet our Team. See our Tech.

Schedule an Intro